Overview

Cardiac Safety of Lansoprazole and Domperidon Combination

Status:
Unknown status
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
The aim of current study is to compare safety and efficacy of lansoprazole/domperidone 30/30 mg sustained release capsules (brand name: Duolans) and lansoprazole 30 mg micropellet capsules (brand name: Lasotab) in GERD patients in terms of cardiac safety.
Phase:
Phase 4
Details
Lead Sponsor:
Neutec Ar-Ge San ve Tic A.Ş
Treatments:
Dexlansoprazole
Domperidone
Lansoprazole